Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. | Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.
GlobalData on MSN6h
BMS wins approval for schizophrenia drug acquired from KarunaThe FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
Hosted on MSN14d
Bristol Myers to Purchase KarunaBristol Myers Squib (NYSE:BMY) on Friday agreed to buy Karuna Therapeutics (NASDAQ:KRTX) for $14 billion in cash, gaining a promising experimental schizophrenia drug to power growth as patents on ...
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback